CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026

  • Report Id: PM1389
  • Published Date: February, 2020
  • No of Pages: 108
  • Format: Electronic (PDF)
  • Publisher: Polaris Market Research
  • Category:

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

Polaris Market research has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region

CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 – 2026)

CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)
CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 – 2026)

Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 – 2026)

U.S.
Europe
Japan
Rest of the World

Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. CAR-T Cell Therapy Market – Premium Insights
3.1. CAR-T Cell Therapy– Industry snapshot
3.2. CAR-T Cell Therapy- Ecosystem analysis
3.3. CAR-T Cell Therapy Market dynamics
3.3.1. CAR-T Cell Therapy– Market Forces
3.3.1.1. CAR-T Cell Therapy Market driver analysis
3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
3.4. Industry analysis – Porter’s five force analysis
3.5. CAR-T Cell Therapy Market PEST analysis, 2019
3.6. CAR-T Cell Therapy Industry trends
3.7. Competitive Ranking Analysis
3.8. Timeline of CAR-T Cell Therapy Development
3.9. CAR-T Cell Manufacturing Process
3.10. Side-effects of CAR-T Cell
3.11. Antigens targeting solid tumors
3.12. Clinical trials Landscape for CAR-T
3.13. Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
3.14. New Innovations in CAR-T therapies
4. CAR-T Cell Therapy Market Size and Forecast 2017 – 2026 by Target Antigen
4.1. Key findings
4.2. CD19/CD22
4.2.1. Global CD19/CD22 market estimates & forecast, 2017 – 2026
4.2.2. Global CD19/CD22 market estimates & forecast, by region, 2017 – 2026
4.3. BCMA (B-Cell Maturation Antigen)
4.3.1. Global BCMA market estimates & forecast, 2017 – 2026
4.3.2. Global BCMA market estimates & forecast, by region, 2017 – 2026
4.4. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
4.4.1. Global Other Target Antigen market estimates & forecast, 2017 – 2026
4.4.2. Global Other Target Antigen market estimates & forecast, by region, 2017 – 2026
5. CAR-T Cell Therapy Market Size and Forecast by Indication
5.1. Key findings
5.2. Diffuse Large B-Cell Lymphoma (DLBCL)
5.2.1. Global DLBCL market estimates & forecast, 2017 – 2026
5.2.2. Global DLBCL market estimates & forecast, by region, 2017 – 2026
5.3. Acute Lymphoblastic Leukemia (ALL)
5.3.1. Global ALL market estimates & forecast, 2017 – 2026
5.3.2. Global ALL market estimates & forecast, by region, 2017 – 2026
5.4. Chronic Lymphocytic Leukemia (CLL)
5.4.1. Global CLL market estimates & forecast, 2017 – 2026
5.4.2. Global CLL market estimates & forecast, by region, 2017 – 2026
5.5. Multiple Myeloma (MM)
5.5.1. Global MM market estimates & forecast, 2017 – 2026
5.5.2. Global MM market estimates & forecast, by region, 2017 – 2026
5.6. Follicular Lymphoma (FL)
5.6.1. Global FL market estimates & forecast, 2017 – 2026
5.6.2. Global FL market estimates & forecast, by region, 2017 – 2026
5.7. Others
5.7.1. Global Other indications market estimates & forecast, 2017 – 2026
5.7.2. Global Other indications market estimates & forecast, by region, 2017 – 2026
6. CAR-T Cell Therapy Market Size and Forecast by Regions
6.1. Key findings
6.2. U.S.
6.2.1. U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2026
6.2.2. U.S. CAR-T Cell Therapy Market by Indication, 2017 – 2026
6.3. Europe
6.3.1. Europe CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026
6.3.2. Europe CAR-T Cell Therapy Market by Indication, 2017 – 2026
6.4. Japan
6.4.1. Japan CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026
6.4.2. Japan CAR-T Cell Therapy Market by Indication, 2017 – 2026
6.5. Rest of the World
6.5.1. RoW CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026
6.5.2. RoW CAR-T Cell Therapy Market by Indication, 2017 – 2026
7. Company Profiles
7.1. Amgen Inc. (US)
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Bellicum Pharmaceuticals, Inc. (US)
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. Bluebird Bio (US)
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Caribou Biosciences, Inc. (US)
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. Celgene Corporation (US) (acquired by Bristol-Myers Squibb)
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Cellectis (France)
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. Celyad (Belgium)
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.7.4. Recent Developments
7.8. Gilead Sciences, Inc. (US)
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments
7.9. Intellia Therapeutics (US)
7.9.1. Overview
7.9.2. Financials
7.9.3. Product Benchmarking
7.9.4. Recent Developments
7.10. Johnson & Johnson (US)
7.10.1. Overview
7.10.2. Financials
7.10.3. Product Benchmarking
7.10.4. Recent Developments
7.11. Mereck KGaA (Germany)
7.11.1. Overview
7.11.2. Financials
7.11.3. Product Benchmarking
7.11.4. Recent Developments
7.12. Nanjing Legend Biotechnology Co., Ltd. (China)
7.12.1. Overview
7.12.2. Financials
7.12.3. Product Benchmarking
7.12.4. Recent Developments
7.13. Noile-Immune Biotech (Japan)
7.13.1. Overview
7.13.2. Financials
7.13.3. Product Benchmarking
7.13.4. Recent Developments
7.14. Novartis International AG (Swiss)
7.14.1. Overview
7.14.2. Financials
7.14.3. Product Benchmarking
7.14.4. Recent Developments
7.15. Pfizer Inc. (US)
7.15.1. Overview
7.15.2. Financials
7.15.3. Product Benchmarking
7.15.4. Recent Developments
7.16. Sangamo Therapeutics, Inc. (US)
7.16.1. Overview
7.16.2. Financials
7.16.3. Product Benchmarking
7.16.4. Recent Developments
7.17. Servier Laboratories (France)
7.17.1. Overview
7.17.2. Financials
7.17.3. Product Benchmarking
7.17.4. Recent Developments

List of Tables
Table 1 Global CAR-T Cell Therapy Market, 2015 – 2026, (USD Million)
Table 2 Global CAR-T Cell Therapy Market by Region, 2015 – 2026, (USD Million)
Table 3 Global CAR-T Cell Therapy Market by Target Antigen, 2015 – 2026, (USD Million)
Table 4 Global CAR-T Cell Therapy Market by Indication, 2015 – 2026, (USD Million)
Table 5 Global CD19/CD22 market estimates & forecast, 2017 – 2026, (USD Million)
Table 6 Global CD19/CD22 market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 7 Global BCMA market estimates & forecast, 2017 – 2026, (USD Million)
Table 8 Global BCMA market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 9 Global Other Target Antigen market estimates & forecast, 2017 – 2026, (USD Million)
Table 10 Global Other Target Antigen market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 11 Global DLBCL market estimates & forecast, 2017 – 2026, (USD Million)
Table 12 Global DLBCL market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 13 Global ALL market estimates & forecast, 2017 – 2026, (USD Million)
Table 14 Global ALL market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 15 Global CLL market estimates & forecast, 2017 – 2026, (USD Million)
Table 16 Global CLL market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 17 Global MM market estimates & forecast, 2017 – 2026, (USD Million)
Table 18 Global MM market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 19 Global FL market estimates & forecast, 2017 – 2026, (USD Million)
Table 20 Global FL market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 21 Global Other indications market estimates & forecast, 2017 – 2026, (USD Million)
Table 22 Global Other indications market estimates & forecast, by region, 2017 – 2026, (USD Million)
Table 23 U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2026, (USD Million)
Table 24 U.S. CAR-T Cell Therapy Market by Indication, 2017 – 2026, (USD Million)
Table 25 Europe CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026, (USD Million)
Table 26 Europe CAR-T Cell Therapy Market by Indication, 2017 – 2026, (USD Million)
Table 27 Japan CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026, (USD Million)
Table 28 Japan CAR-T Cell Therapy Market by Indication, 2017 – 2026, (USD Million)
Table 29 RoW CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026, (USD Million)
Table 30 RoW CAR-T Cell Therapy Market by Indication, 2017 – 2026, (USD Million)

List of Figures
FIG. 1 Market snapshot
FIG. 2 Market segmentation
FIG. 3 CAR-T Cell Therapy — Market size and growth prospects
FIG. 4 CAR-T Cell Therapy — Value chain analysis
FIG. 5 Market dynamics
FIG. 6 Porter’s five forces analysis
FIG. 7 Penetration & growth prospect mapping
FIG. 8 Key Company Analysis, 2019
FIG. 9 CAR-T Cell Therapy — PEST analysis
FIG. 10 CAR-T Cell Therapy Market: Target Antigen Share Analysis
FIG. 11 CAR-T Cell Therapy Market: Indication Share Analysis
FIG. 12 Regional market place: Key takeaways

Choose License Type

Single user
$3,950
Multi User
$4,950
Enterprise User
$5,950
Clear

Each market study on Reports Globe will be revised based on COVID-19 impact analysis

How can we help you?

Our salient features

Best Solution

We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.

Customized Research

Our team of analysts and consultants provide assistance for customized research requirements

Max ROI

Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.

24/7 Support

24X7 availability to help you through the buying process as well as answer any of your doubts.

We've Received Your Request

We Thank You for filling out your requirements. Our sales team will get in touch with you shortly.